KineMed, Bristol-Myers Squibb Extend Collaboration Covering Alzheimer's Disease

Under the extension, KineMed is granting Bristol-Myers Squibb a non-exclusive license to KineMed's technology for the identification and characterization of AD biomarkers in cerebrospinal fluid.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.